Indacaterol is a long-acting beta2-adrenergic agonist indicated for:

• The long term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

COPD

Bronchitis

Emphysema

One capsule of Indacaterol should be administered once daily every day at the same time of the day by the orally inhaled route only. If a dose is missed, the next dose should be taken as soon as it is remembered.  Do not use Indacaterol more than one time every 24 hours. 

Inhalation Capsule

The most common side effects are as follows-

• cough
• oropharyngeal pain
• nasopharyngitis
• headache
• nausea

Coughing

Nasopharyngitis

Headache

Nausea

• Long-acting beta2-adrenergic agonists (LABA) raise the risk of death from asthma.
• In a placebo-controlled study with another long-acting beta2adrenergic agonist (salmeterol), patients receiving salmeterol had an increase in asthma-related deaths.
• The discovery of an increased risk of asthma-related death with salmeterol is regarded as a class effect of LABA, which includes indacaterol, the active ingredient in Indacaterol. Indacaterol's safety and efficacy in patients with asthma have not been established. Indacaterol is not intended to be used to treat asthma.
• Do not initiate in acutely deteriorating COPD patients
• Do not use for relief of acute symptoms. Concomitant short-acting beta2 agonists can be used as needed for acute relief
• Do not exceed the recommended dose.  Excessive use or use in conjunction with other medications containing LABA can result in clinically significant cardiovascular effects and may be fatal
• Immediate hypersensitivity reactions may occur. Discontinue immediately.
• Life-threatening paradoxical bronchospasm can occur. Discontinue immediately.
• Use with caution in patients with cardiovascular or convulsive disorders, thyrotoxicosis or sensitivity to sympathomimetic drugs.